A study of hepatocellular carcinoma patients surviving for 10 years—Comparison of hepatectomy and percutaneous ablation therapy—

概要

論文の詳細を見る
We examined the characteristics of hepatocellular carcinoma patients with 10-year survival who had received initial treatment and been followed up for more than 10 years at our hospital. The 10-year survival rate was 12%, and comparison of patients who survived for 10 years (n = 36) and those who did not (n = 265) showed that the former had better hepatic functional reserve, with mild tumor progression and rates of usage of post-treatment interferon therapy and performance of hepatectomy. Comparison of patients with hepatectomy (n = 24) and those with percutaneous ablation therapy (n = 10) who survived for 10 years showed that those with hepatectomy had lower total bilirubin values, higher platelet counts, and larger tumor diameters. The total number of treatments in patients with tumor recurrence who survived for 10 years was 9.6 ± 5.2 in the case of hepatectomy and 14.6 ± 8.0 in the case of percutaneous ablation therapy. These findings suggest that repeated treatment can lead to long-term survival in patients with good hepatic functional reserve in whom initial treatment is radical and in whom subsequent periodic follow-up yields early detection of tumor recurrences.